Cargando…
Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
Objective: To evaluate the efficacy and safety of low-dose mycophenolate mofetil (MMF, 1,000 mg/day) treatment of neuromyelitis optica spectrum disorders (NMOSDs). Methods: This study was a multicenter, open, prospective, follow-up clinical trial. The data include retrospective clinical data from th...
Autores principales: | Huang, Qiao, Wang, Jingqi, Zhou, Yifan, Yang, Hui, Wang, Zhanhang, Yan, Zhenwen, Long, Youming, Yin, Jia, Feng, Huiyu, Li, Caixia, Lu, Zhengqi, Hu, Xueqiang, Qiu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143768/ https://www.ncbi.nlm.nih.gov/pubmed/30258442 http://dx.doi.org/10.3389/fimmu.2018.02066 |
Ejemplares similares
-
Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study
por: Jiao, Yujuan, et al.
Publicado: (2018) -
Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis
por: Songwisit, Sakdipat, et al.
Publicado: (2020) -
Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis
por: Han, Mengyu, et al.
Publicado: (2020) -
Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2020) -
Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
por: Lin, Jie, et al.
Publicado: (2022)